The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.
Chronic Kidney Disease (CKD)
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
-
Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048
University of California Irvine, Orange, California, United States, 92868
Connie Frank Transplant Center at UCSF, San Francisco, California, United States, 94143
Yale University of Medicine, New Haven, Connecticut, United States, 06520
Comprehensive Transplant Center, Chicago, Illinois, United States, 60611
John Hopkins Hospital, Baltimore, Maryland, United States, 21224
New York University Langone Health, New York, New York, United States, 10016
Penn Transplant Institute, Philadelphia, Pennsylvania, United States, 19104
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 70 Years
ALL
No
Regeneron Pharmaceuticals,
Clinical Trial Management, STUDY_DIRECTOR, Regeneron Pharmaceuticals
2027-12-24